• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Marc B. Garnick, MD


  • Garnick MB.Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.J Clin Oncol. 2013 Oct 20;31(30):3746-8.
  • Garnick MB.Possible confusion in names of new treatments for prostate cancer.N Engl J Med. 2013 Jan 10;368(2):194.
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2011 Feb;185(2):471-6.
  • Garnick MB.Editorial comment.Urology. 2010 Jun;75(6):1428-30; author reply 1430.
  • Garnick MB.Screening and detection of breast cancer and prostate cancer.JAMA. 2010 Mar 17;303(11):1033; author reply 1033-4.
  • Garnick MB.Important considerations in LHRH antagonist therapy for prostate cancer.Oncology (Huntingt). 2009 Jun;23(7):636-7.
  • Garnick MB.Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized data.J Clin Oncol. 2007 Oct 1;25(28):4337-8.
  • Debruyne F, Bhat G, Garnick MB.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.Future Oncol. 2006 Dec;2(6):677-96. Review.
  • Beer TM, Ryan C, Bhat G, Garnick M,.Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.Anticancer Drugs. 2006 Oct;17(9):1075-9.
  • Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.J Urol. 2006 Aug;176(2):520-5.
  • Garnick MB, Fair WR.Combating prostate cancer.Sci Am. 1998 Dec;279(6):74-83.
  • Jakubowski AA, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN.Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.Clin Cancer Res. 1996 Feb;2(2):295-302.
  • Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, Garnick MB, Porterfield HA.Comparison of perspectives on prostate cancer: analyses of survey data.Urology. 1997 Sep;50(3):366-72.
  • Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP.Leydig cell hyperplasia mimicking testicular neoplasm.Urology. 1996 Oct;48(4):647-9.
  • Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA.A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.Blood. 1996 May 1;87(9):3607-14.
  • Stoudemire JB, Garnick MB.Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels.Blood. 1991 Feb 15;77(4):750-5.
  • Garnick MB, Abels R, Rudnick SA.The role of recombinant human erythropoietin in the management of anemia associated with acquired immunodeficiency syndrome.Contrib Nephrol. 1991;88:282-92; discussion 293-4.